- Home
- ELVN vs HIMX Comparison
ELVN vs HIMX Comparison
Compare ELVN & HIMX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ELVN
- HIMX
- Stock Information
- Founded
- ELVN 2016
- HIMX 2001
- Country
- ELVN United States
- HIMX Taiwan
- Employees
- ELVN N/A
- HIMX N/A
- Industry
- ELVN Biotechnology: Pharmaceutical Preparations
- HIMX Semiconductors
- Sector
- ELVN Health Care
- HIMX Technology
- Exchange
- ELVN Nasdaq
- HIMX Nasdaq
- Market Cap
- ELVN 1.1B
- HIMX N/A
- IPO Year
- ELVN 2020
- HIMX 2006
- Fundamental
- Price
- ELVN $22.04
- HIMX $11.80
- Analyst Decision
- ELVN Strong Buy
- HIMX Buy
- Analyst Count
- ELVN 5
- HIMX 1
- Target Price
- ELVN $37.80
- HIMX $15.00
- AVG Volume (30 Days)
- ELVN 221.0K
- HIMX 2.9M
- Earning Date
- ELVN 03-13-2025
- HIMX 02-13-2025
- Dividend Yield
- ELVN N/A
- HIMX 2.46%
- EPS Growth
- ELVN N/A
- HIMX 10.98
- EPS
- ELVN N/A
- HIMX 0.44
- Revenue
- ELVN N/A
- HIMX $897,257,000.00
- Revenue This Year
- ELVN N/A
- HIMX $12.75
- Revenue Next Year
- ELVN N/A
- HIMX N/A
- P/E Ratio
- ELVN N/A
- HIMX $22.54
- Revenue Growth
- ELVN N/A
- HIMX N/A
- 52 Week Low
- ELVN $10.90
- HIMX $4.80
- 52 Week High
- ELVN $30.03
- HIMX $12.40
- Technical
- Relative Strength Index (RSI)
- ELVN 45.17
- HIMX 79.73
- Support Level
- ELVN $21.45
- HIMX $8.59
- Resistance Level
- ELVN $22.82
- HIMX $8.62
- Average True Range (ATR)
- ELVN 1.61
- HIMX 0.79
- MACD
- ELVN -0.01
- HIMX 0.29
- Stochastic Oscillator
- ELVN 36.08
- HIMX 88.70
About ELVN Enliven Therapeutics Inc.
Enliven Therapeutics Inc is a clinical-stage precision oncology company focused on the discovery and development of potentially first-in-class precision oncology therapies. Enliven's programs are designed to address issues such as tolerability, combinability, resistance and disease escape through brain metastases. Its product candidates include ELVN-001 which is a potent, selective, small molecule kinase inhibitor designed to specifically target the BCR-ABL gene fusion, the oncogenic driver for patients with chronic myeloid leukemia, and the ELVN-002 which is central nervous system (CNS) penetrant and irreversible HER2 inhibitor with activity against wild type HER2 and various HER2 mutations.